Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
The DOI matches its Crossref record.
Abstract
LDL (low-density lipoprotein) is the major carrier of cholesterol in human plasma, and as such is intimately involved in the process of atherosclerosis. The lipoprotein class comprises a number of distinct subfractions, and is commonly divided into large, intermediate and small sized particles. Small, dense LDLs are held to be particularly atherogenic, since these particles are retained preferentially by the artery wall, are readily oxidized and carry an enzyme believed to have an important role in atherosclerosis, i.e. lipoprotein-associated phospholipase A2. Generation of small, dense LDL occurs by intravascular lipoprotein remodelling as a result of disturbances such as Type II diabetes, metabolic syndrome, renal disease and pre-eclampsia. The key predisposing factor is the development of hypertriglyceridaemia, in particular elevation in the plasma concentration of large, triacylglycerol-rich VLDL (very-low-density lipoprotein). This leads to the formation of slowly metabolized LDL particles (5-day residence time), which are subject to exchange processes that remove cholesteryl ester from the particle core and replace it with triacylglycerol. LDL, so altered, is a potential substrate for hepatic lipase; if the activity of the enzyme is high enough, lipolysis will generate smaller, denser particles. Correction of the dyslipidaemia associated with small, dense LDL is possible using fibrates and statins, and this may contribute to the clinical benefits seen with these drugs. Fibrates act to lower plasma triacylglycerol (VLDL) levels, and so correct the underlying metabolic disturbance. Statins remove VLDL particles via receptor-mediated pathways and reduce the residence time (and hence limit the potential for remodelling) of LDL in the circulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Small dense LDL are relatively slowly metabolized with a five day residence time, which enhances its atherogenicity [54].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [54]
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 227
Lofgren, I. E., Herron, K. L., West, K. L., Zern, T. L., Patalay, M., Koo, S. I., & Fernández, M. L. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.12.008 · Cited by 30
Hieronimus, B., Griffen, S. C., Keim, N. L., Bremer, A. A., Berglund, L., Nakajima, K., Havel, P. J., & Stanhope, K. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070913 · Cited by 28
Stolinski, M., Alam, S., Jackson, N. C., Shojaee‐Moradie, F., Pentecost, C., Jefferson, W., Christ, E., Jones, R. H., & Umpleby, A. M. (2008) · Metabolism · doi:10.1016/j.metabol.2008.06.018 · Cited by 32
Agouridis, A. P., Kostapanos, M. S., Tsimihodimos, V., Kostara, C. E., Mikhailidis, D. P., Bairaktari, E. T., Tselepis, A. D., & Elisaf, M. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02972.x · Cited by 28
Adal, M., Howe, R., Kassa, D., Aseffa, A., & Petros, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195942 · Cited by 25
Small dense low-density lipoprotein-lowering agents
Alizadeh‐Fanalou, S., Nazarizadeh, A., Alian, F., Faraji, P., Sorori, B., & Khosravi, M. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0426 · Cited by 28
Mohan, V., Deepa, R., Velmurugan, K., & Gokulakrishnan, K. (2005) · PubMed · Cited by 25
Egeland, G. M., Igland, J., Sulo, G., Nygard, O. K., Ebbing, M., & Tell, G. S. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314535681 · Cited by 25
Julius, U., Dittrich, M., & Pietzsch, J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01507.x · Cited by 24
Chunta, S., Boonsriwong, W., Wattanasin, P., Naklua, W., & Lieberzeit, P. A. (2020) · Talanta · doi:10.1016/j.talanta.2020.121549 · Cited by 24
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 29
Association between omega-3 index and blood lipids in older Australians
Ferguson, J. J. A., Veysey, M. J., Lucock, M. D., Niblett, S. H., King, K., MacDonald‐Wicks, L. K., & Garg, M. L. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.09.010 · Cited by 23
Circadian change of serum concentration of small dense LDL-cholesterol in type 2 diabetic patients
Hirayama, S., Soda, S., Ito, Y., Matsui, H., Ueno, T., Fukushima, Y., Ohmura, H., Hanyu, O., Aizawa, Y., & Miida, T. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.11.017 · Cited by 21
Protein profiling of low‐density lipoprotein from obese subjects
Karlsson, H., Mörtstedt, H., Lindqvist, H. M., Tagesson, C., & Lindahl, M. G. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800138 · Cited by 21
Effect of 8-weeks intensive lifestyle intervention on LDL and HDL subfractions
Bajer, B., Rádiková, Ž., Havranová, A., Žitňanová, I., Vlček, M., Imrich, R., Sabaka, P., Bendžala, M., & Penesová, A. (2019) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2019.10.010 · Cited by 23
Tian, L., Xu, Y., Fu, M., Peng, T., Liu, Y., & Long, S. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-17 · Cited by 21
Increased lipolysis by secretory phospholipase A2 group V of lipoproteins in diabetic dyslipidaemia
Pettersson, C., Fogelstrand, L., Rosengren, B. E., Ståhlman, S., Hurt‐Camejo, E., Fagerberg, B., & Wiklund, O. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01932.x · Cited by 21
Nakano, K., Hasegawa, G., Fukui, M., Yamasaki, M., Ishihara, K., Takashima, T., Kitagawa, Y., Fujinami, A., Ohta, M., Hara, H., et al. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-006 · Cited by 21
Durrington, P. N., Bashir, B., & Soran, H. (2025) · Antioxidants · doi:10.3390/antiox14040430 · Cited by 22
Onat, A., Can, G., Çiçek, G., Ayhan, E., & Doğan, Y. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.08.027 · Cited by 20
Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications
Syed, T., & Siddiqui, M. S. (2021) · Liver Transplantation · doi:10.1002/lt.26069 · Cited by 18
Triglycerides and coronary heart disease: have recent insights yielded conclusive answers?
Sarwar, N., & Sattar, N. A. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd4dc · Cited by 19
Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome
Hernández‐Mijares, A., Bañuls, C., Gómez‐Balaguer, M., Bergoglio, M. T., Víctor, V. M., & Rocha, M. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12080 · Cited by 18
Sabaka, P., Kruzliak, P., Balaz, D., Komornikova, A., Celovska, D., Cammarota, G., Kusendova, K., Bendzala, M., Rodrigo, L., Dukat, A., et al. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0148-5 · Cited by 16
Chemerin as a Driver of Cardiovascular Diseases: New Perspectives and Future Directions
Imiela, A. M., Stępnicki, J., Zawadzka, P. S., Bursa, A., & Pruszczyk, P. (2025) · Biomedicines · doi:10.3390/biomedicines13061481 · Cited by 17
Boumaiza, I., Omezzine, A., Rejeb, J., Rebhi, L., Kalboussi, N., Rejeb, N. B., Nabli, N., Abdelaziz, A. B., Boughazala, E., & Bouslama, A. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0006 · Cited by 16
Torres‐Gonzalez, M., Volek, J. S., Sharman, M. J., Contois, J. H., & Fernández, M. L. (2006) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.01.004 · Cited by 16
Yıldız, G., Hür, E., Özçiçek, A., Candan, F., & Kayataş, M. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2012.689043 · Cited by 15
Sorokin, A. V., Patel, N. H., Li, H., Hong, C. G., Sampson, M. L., O’Hagan, R., Florida, E. M., Teague, H., Playford, M. P., Chen, M. Y., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01819-x · Cited by 14
Evaluation of the Hypoglycemic Properties ofAnacardium humileAqueous Extract
de Urzêda, M. A., Marcussi, S., Pereira, L. L. S., França, S. D. C., Pereira, A. M. S., Pereira, P. S., Silva, S. L. D., Guimarães, C. L. S., Calderón, L. A., Stábeli, R. G., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/191080 · Cited by 14
Parveen, S., Jacob, R. T., Rajasekhar, L., Srinivasa, C., & Mohan, I. K. (2016) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-016-0566-9 · Cited by 15
The metabolic syndrome: A vascular perspective
Tamsma, J. T., Jazet, I. M., Beishuizen, E. D., Fogteloo, A. J., Meinders, A. E., & Huisman, M. V. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.01.011 · Cited by 13
Lin, K.-H., Gómez, E. V., Corey, K. E., Connelly, M. A., Gupta, S. K., Lake, J. E., Chalasani, N., & Gawrieh, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02317-4 · Cited by 12
Kumpula, L. S., Mäkelä, S. M., Mäkinen, V., Karjalainen, A. H., Liinamaa, J., Kaski, K. K., Savolainen, M. J., Hannuksela, M. L., & Ala‐Korpela, M. (2009) · Journal of Lipid Research · doi:10.1194/jlr.d000760 · Cited by 14
Chapter 8 Atherogenic Lipoprotein Subprofiling
Ellington, A. A., & Kullo, I. J. (2008) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)00408-3 · Cited by 16
Maki, K. C., Dicklin, M. R., Davidson, Mize, P. D., & Kulkarni, K. R. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s27963 · Cited by 11
Predictors of Low-Density Lipoprotein Particle Size in a High-Risk African-American Population
Benton, J. L., Blumenthal, R. S., Becker, D. M., Yanek, L. R., Moy, T. F., & Post, W. S. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.075 · Cited by 14
Yang, Q., Xiang, W. D., Khan, A., Salama, E., Kulshrestha, S., Ji, J., Wu, Y., & Li, X. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2531198 · Cited by 11
Hulander, E., Bärebring, L., Winkvist, A., Gjertsson, I., & Lindqvist, H. M. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03451-6 · Cited by 12
Morton, R. E., & Izem, L. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m056333 · Cited by 10
Perioperative Heart-Brain Axis Protection in Obese Surgical Patients: The Nutrigenomic Approach
Agrimi, J., Baroni, C., Anakor, E., & Lionetti, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181015145225 · Cited by 10
Thuyen, T. Q., Dương, Đ. H., Nga, B. T. T., Ngọc, N. A., Duong, L. T., Phương, P. T., Nhung, B. T., & Bình, T. Q. (2021) · Endocrine · doi:10.1007/s12020-021-02836-5 · Cited by 10
More Clinical Lessons from the FIELD Study
Fazio, S. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6160-5 · Cited by 12
Minarikova, Z., Gašpar, Ľ., Kružliak, P., Celecová, Z., & Oravec, S. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-158 · Cited by 10
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W., & Walford, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00041-x · Cited by 13
Bevilacqua, M. T., Righini, V., Barrella, M., Vago, T., Chebat, E., & Dominguez, L. J. (2005) · Advances in Therapy · doi:10.1007/bf02849947 · Cited by 10
New Concepts in Dyslipidemia in the Metabolic Syndrome and Diabetes
Davidson, M. H., & Yannicelli, H. D. (2006) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2006.4.299 · Cited by 11
LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study?
Chan, D. C., & Watts, G. F. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01420.x · Cited by 9
Seely, E. W., & Grinspoon, S. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00002-8 · Cited by 11
Connelly, M. A., Rivera, J. V., Guyton, J. R., Siddiqui, M. S., & Sanyal, A. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15935 · Cited by 11
Sanchez, D., León, E. M., Salgado, C. N. A., Martinez, Y. S., Figueroa, P. D., Escárcega, M. C., Cohen, A. H., Garcia, X. A. S., Guzman, J. A. R., & Haro, S. E. R. (2025) · Cureus · doi:10.7759/cureus.97204 · Cited by 13
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., Yamamoto, T., Ohara, M., Terasaki, M., Kushima, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14076 · Cited by 10
Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension
Oravec, S., Dukát, A., Gavorník, P., Čaprnda, M., Kucera, M., & Očadlík, I. (2011) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03657562 · Cited by 8
Shahsavari, G., Raoufi, A., Toolabi, A., Hosseninejadmir, N., Ahmadvand, H., & Safariebrahimsarabie, M. (2017) · Europe PMC (PubMed Central) · Cited by 8
Mertens, I. L., Lemieux, I., Verrijken, A., Després, J., & Gaal, L. F. V. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.779 · Cited by 8
Nantakool, S., Punturee, K., Konghakote, S., Sittichoke, C., Phirom, K., & Chuatrakoon, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010044 · Cited by 6
Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
Maki, K. C., Benes, L. B., & Dicklin, M. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_16 · Cited by 8
Wang, K., Li, Z., Zhang, W., Liu, Y., Wang, X., Sun, M., Fang, X., & Han, W. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105964 · Cited by 6
Predictive value of plasma lipid levels for coronary artery disease (CAD)
Shahid, S. U., Shabana, N. A., & Rehman, A. (2020) · Biologia · doi:10.2478/s11756-020-00448-4 · Cited by 10
Moriyama, K., Urata, N., Masuda, Y., Oda, K., Okuno, C., Yamada, C., Takashimizu, S., Akira, K. U. B. O., Kishimoto, N., & Nishizaki, Y. (2021) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0121 · Cited by 6
Guri, A. J., Hontecillas, R., & Bassaganya-Riera, J. (2008) · Lifestyle Genomics · doi:10.1159/000112460 · Cited by 6
LDL resistance to oxidation: Effects of lipid phenotype, autologous HDL and alanine
Baldi, S., Frascerra, S., Ferrannini, E., & Natali, A. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.12.019 · Cited by 6
Rocha, M., Bañuls, C., Bellod, L., Rovira‐Llopis, S., Morillas, C., Solá, E., VÃctor, V. M., & Mijares, A. H. (2013) · PLoS ONE · doi:10.1371/annotation/4ee4f5f7-519f-402c-8ed2-dff0cc6c5e48 · Cited by 6
Kirwan, R., Mazidi, M., Butler, T., de Heredia, F. P., Lip, G. Y. H., & Davies, I. G. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae019 · Cited by 5
Diallo, A. F., Abbas, M., Goodney, G. A., Price, E. T., & Gaye, A. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00332.2024 · Cited by 5
Laupsa‐Borge, J., Grytten, E., Bohov, P., Bjørndal, B., Strand, E., Skorve, J., Nordrehaug, J. E., Berge, R. K., Rostrup, E., Mellgren, G., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1020678 · Cited by 6
Insulin resistance and the metabolic syndrome
Krentz, A. J., & Scuteri, A. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch15 · Cited by 5
LDL Subclasses in Ischemic Stroke: A Risk Factor?
Kayran, Y., Yayla, V., Çabalar, M., Bajrami, A., Karamanlı, Y., Gedikbaşı, A., & Tanrıverdi, Z. (2017) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2017.19393 · Cited by 6
Matsumori, R., Tanaka, M., Sato, T., Akiyama, Y., Hosaka, I., Nakata, K., Kawaharata, W., Aida, H., Nishizawa, K., Kouzu, H., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65939 · Cited by 4
Gungor, A., Balamtekın, N., Özkeçeci, C. F., & Aydın, H. İ. (2021) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2021.24.5.483 · Cited by 4
Alireza, H. (2021) · International Journal of Membrane Science and Technology · doi:10.15379/2410-1869.2021.08.02.05 · Cited by 5
Small Dense LDL Particles in Relation to LDL Oxidation in Normolipidemic CAD Patients
(2011) · The Internet Journal of Cardiovascular Research · doi:10.5580/2548 · Cited by 4
Šiarnik, P., Čarnická, Z., Krivošíková, Z., Klobučníková, K., Žitňanová, I., Kollár, B., Sykora, M., & Turčáni, P. (2016) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2016.1243257 · Cited by 5
Epidemiologic Characterization of Risk for Cardiovascular Diseases
Maki, K. C., Dicklin, M. R., & Nieman, K. M. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_1 · Cited by 5
Relación entre la obesidad central y los componentes del síndrome metabólico
Coniglio, R. I. (2014) · Acta bioquímica clínica latinoamericana/Acta bioquímica clínica latinoamericana · Cited by 17
Ghassab, R. K., Gohari, L. H., Firoozrai, M., & Yegane, M. N. (2010) · Laboratory Medicine · doi:10.1309/lmr1mwbggi3kxzei · Cited by 4
Oravec, S., Gruber, K., Dukát, A., Gavorník, P., Gašpar, Ľ., & Dostal, E. (2015) · InTech eBooks · doi:10.5772/60989 · Cited by 4
A Non-Atherogenic and Atherogenic Lipoprotein Profile in Individuals with Dyslipoproteinemia
Oravec, S., Mikl, J., Gruber, K., & Dostal, E. (2012) · InTech eBooks · doi:10.5772/46067 · Cited by 4
Alireza, H. (2021) · International Journal of Membrane Science and Technology · doi:10.15379/2410-1869.2021.08.02.04 · Cited by 3
Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes
Cobble, M. E., Mize, P. D., & Brinton, E. A. (2013) · Contemporary diabetes · doi:10.1007/978-1-4614-7554-5_2 · Cited by 3
Influence of dietary treatment on lipid metabolism in metabolic syndrome.
Teparić, R., Landeka, I., Tomić, J., & Đikić, D. (2012) · Hrvatski časopis za prehrambenu tehnologiju biotehnologiju i nutricionizam · Cited by 2
Duran, E. K., Cook, N. R., Aday, A. W., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.123.039381 · Cited by 4
Nutrition Therapy for Diabetes and Lipid Disorders
Zimmerman, J., & Karmally, W. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580406482.ch15 · Cited by 2
Yan, F., Tian, L., Xiao, Z., Li, S.-Y., Fu, M., & Tian, H. (2014) · Clinical Lipidology · doi:10.2217/clp.14.11 · Cited by 2
VenkataRamana, C. (2014) · IOSR Journal of Pharmacy and Biological Sciences · doi:10.9790/3008-09341318 · Cited by 2
Omega-3 Polyunsaturated Fatty Acids and Hyperlipidaemias
Ferguson, J. J. A., Dias, C. B., & Garg, M. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-40458-5_6 · Cited by 3
Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?
Samanta, B. (2019) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0039-1697239 · Cited by 1
A Conversation about Healthy Eating
Lesica, N. A. (2017) · UCL Press eBooks · doi:10.14324/111.9781911576754 · Cited by 1
Dyslipidemia and Cardiovascular Risk in Obesity
Arca, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-09045-0_12 · Cited by 2
Maki, K. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_4 · Cited by 1
Atalay, S., Singer, R., Kayadibi, H., Yekrek, M. M., & Kurcenli, S. (2011) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2011.68552 · Cited by 1
20. Bariatric surgery for modified cholesterol metabolism
Benetti, A., Garbossa, S., & Pontiroli, A. E. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-821-6_20 · Cited by 1
N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease
Barringer, T. A., Harris, W. S., Fleming, J. A., & Kris‐Etherton, P. M. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_21 · Cited by 1
Correlation of T3, T4 and TSH with lipid indices in obesity
Aruna, V. (2021) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20212527 · Cited by 1
Association of Lipid Profile with Sleep-Disordered Breathing in Patients with Acute Ischemic Stroke
Šiarnik, P., Kollár, B., Filippi, P., Klobučníková, K., Hlucháňová, A., Žitňanová, I., & Turčáni, P. (2020) · Journal of Stroke Medicine · doi:10.1177/2516608520919211 · Cited by 1
Studies on the atherogenicity of apoB-containing lipoproteins in type 2 diabetes
Pettersson, C. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 2
Boyle, J. A. (2011) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 2
Cardiovascular Epidemiology and Characterization of Atherosclerotic Disease Risk Factors
Maki, K. C., & Rubin, M. R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-963-5_1
Lipoproteins in Diabetes: Risk and Opportunity
Guyton, J. R. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_17 · Cited by 1
The role of B-glucan, plant stanols, and oxy(phyto)sterols in managing cardiovascular risk
Theuwissen, E. (2008) · Research Publications (Maastricht University) · doi:10.26481/dis.20081217et · Cited by 1
Metadata
- Authors
- Packard, C. J.
- Affiliations
- Glasgow Royal Infirmary (GB)
- Corresponding author
- Packard, C.J.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2003-10-01
- Volume
- 31
- Issue
- 5
- Pages
- 1066-1069
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2121209370
- Cited by
- 225
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 13 · 2020: 12 · 2019: 6 · 2018: 7 · 2017: 12 · 2016: 9 · 2015: 15 · 2014: 13 · 2013: 10 · 2012: 11
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- small dense LDL, triglyceride-rich lipoproteins, VLDL, hypertriglyceridemia, hepatic lipase, lipolysis, atherosclerosis, lipoprotein-associated phospholipase A2, fibrates, statins, dyslipidemia, cholesterol esters
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Lipoproteins, Lipoproteins, LDL, Models, Biological, Phospholipases A, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.